Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer.

摘要: Background Thymoquinone (TQ) is a bioactive phytoconstituent obtained from Nigella sativa (black seeds). It has promising potential in cancer prevention. Objective Previous studies have shown that TQ can modulate signaling pathways responsible for progression, thus enhancing the efficacy and improving safety profile of clinically used anticancer drugs. Method acts on cell cycle inhibits progression G1 to S phase by targeting various proteins (cyclin D1, cyclin E, p27). also exhibits histone deacetylase (HDAC) inhibitory effects, targets p21 Maspin, induces pro-apoptotic gene, Bax downregulates anti-apoptotic gene Bcl-2. Breast (BC) reported as one most common malignancies women. Results Despite research advancement, it remains causes related deaths among Recent advancements molecular screening BC led identification challenging condition triple negative breast (TNBC). TNBC characterized absence targetable receptors viz. estrogen receptor (ER), progesterone (PR) human epidermal growth factor 2 (HER2) expressions. reduced or phosphatase tensin homolog (PTEN) expression, tumor suppressor having diverse functions including regulation apoptosis, cycle, metastasis. Conclusion Since been up-regulate several factors such vascular endothelial (VEGF), EGF PTEN present review article discusses therapeutic intervention against types cancer.